Stockreport

resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease

RESTORBIO  (TORC) 
Last restorbio earnings: 3/12 07:30 am Check Earnings Report
PDF BOSTON, Jan. 31, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the [Read more]